Primary Aldosteronism

Author/s: 
Emily P. Marogi, Lisa Dubrofsky, Robert J. Weber
Date Added: 
September 9, 2026
Journal/Publication: 
JAMA Intern Med
Publisher: 
The American Medical Association
Publication Date: 
September 8, 2026
Pages: 
E1-E2
Type: 
Meta-analyses, Reviews, and Guidelines
CME Credits: 
1
Format: 
Article
DOI (1): 
doi: 10.1001/jamainternmed.2026.4155

RPR Commentary

RPR Commentary: A review of primary aldosteronism, a treatable condition present in approximately 6% in adult primary care patients to 29% of patients with treatment-resistant hypertension. James W. Mold, MD, MPH

Abstract

Primary aldosteronism (PA) is an endocrine disorder that results from aldosterone overproduction by the adrenal glands, independent of physiological stimuli (hyperkalemia or renin). Symptomatic PA can cause hypertension and hypokalemia, but PA exists across a spectrum of severity from subclinical disease to treatment-resistant hypertension and from normokalemia to severe hypokalemia. PA remains underdiagnosed despite the fact that targeted therapies can reduce morbidity and mortality.1,2 This Clinical Insights article provides clinicians with a practical approach to diagnosing and managing PA.

Text Availability

Free full text